Biomea Fusion stock analysis
Want to see BMEA full AI Analyst Report?
Biomea Fusion (BMEA) Stock Price & Analysis
BMEA Stock Chart & Stats
- Day’s Range
- $0.54 - $0.60
- 52-Week Range
- $0.45 - $2.24
- Previous Close
- $0.59
- Volume
- N/A
- Average Volume (3M)
- 2.10M
- Market Cap
- $42.76M
- Enterprise Value
- $70.28M
- Total Cash (Recent Filing)
- $26.40M
- Total Debt (Recent Filing)
- $506.00K
- Price to Earnings (P/E)
- ―
- Beta
- 2.02
- Next Earnings
- Mar 30, 2027 (Est.)
- EPS Estimate
- -0.21
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
BMF-650 Phase 1 Progress
The Phase 1 readout advances BMF-650 into human clinical development and supports continued assessment of its oral GLP-1 approach. Its stated focus on tolerability, one-step titration and bioavailability could provide durable product differentiation if later trials confirm these benefits.
Improving Loss Trend
The substantial reduction in reported net losses indicates meaningful cost containment or lower operating spend over successive periods. Although the company remains unprofitable, a lower expense base can extend development resources and improve financial flexibility while clinical programs advance.
Low Financial Leverage
Low leverage limits fixed debt obligations and reduces the balance sheet's exposure to interest and refinancing pressure. This gives management more flexibility to direct available capital toward clinical development, although it does not remove the need for future funding.
Bears Say
Pre-Revenue Business Model
The absence of product revenue means Biomea currently lacks commercial operating leverage and must fund research and development before establishing a recurring revenue base. This leaves future financial performance highly dependent on clinical progress and eventual product commercialization.
Persistent Cash Burn
Ongoing negative operating and free cash flow indicates that the business is not yet self-funding its development activities. Continued reliance on external capital can constrain strategic flexibility and create durable financing risk until a product generates meaningful cash receipts.
Eroding Equity Base
The sharp decline in shareholders' equity shows that accumulated losses have materially reduced the capital base. A thinner equity cushion leaves less room to absorb setbacks and may increase dependence on future financing to sustain clinical programs and operating commitments.
Biomea Fusion News
Biomea Fusion: Unchanged $7 Price Target as Icovamenib Catalysts and GLP-1 Upside Drive Buy Case Despite Funding Risk
Yigal Nochomovitz, an analyst from Citi, maintained the Buy rating on Biomea Fusion. The associated price target remains the same with $7.00. Yigal Nochomovitz’s rating is based on several factors,
Biomea Fusion announces Phase 1 GLP-131 clinical trial results for BMF-650
Biomea Fusion (BMEA) announced Phase 1 GLP-131 clinical trial results for BMF-650, its investigational oral small-molecule glucagon-like peptide-1 receptor agonist, or GLP-1 RA”, which demonstrated consistent weight reduction across five
Biomea Fusion Completes Phase 1 BMF-500 Trial in Acute Leukemia: What Investors Should Watch Next
Biomea Fusion Inc ($BMEA) announced an update on their ongoing clinical study. Biomea Fusion Inc. is running a Phase 1 study called “A Phase 1, Open-label, Dose-escalation, and Dose-expansion Study
BMEA FAQ
What was Biomea Fusion’s price range in the past 12 months?
What is Biomea Fusion’s market cap?
When is Biomea Fusion’s upcoming earnings report date?
How were Biomea Fusion’s earnings last quarter?
Is Biomea Fusion overvalued?
Does Biomea Fusion pay dividends?
What is Biomea Fusion’s EPS estimate?
How many shares outstanding does Biomea Fusion have?
What happened to Biomea Fusion’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Biomea Fusion?
What is the TipRanks Smart Score and how is it calculated?
Biomea Fusion Stock Smart Score
Company Description
Biomea Fusion
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It’s lead clinical program’s drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes. The company is also developing BMF-650, which is in Phase I glucagon-like peptide-131 clinical trial for the treatment of obesity. The company was incorporated in 2017 and is headquartered in San Carlos, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Michael J. Hitchcock
- Employees
- 41
- Website
- biomeafusion.com
- Address
- 1599 Industrial Road, San Carlos, CA, 94070, US
Biomea Fusion (BMEA) Earnings & Revenues
BMEA Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 5 | 6 | 11 |
| Technical Analysis | 1 | 6 | 3 |
| Moving Averages | 4 | 0 | 8 |












